News
OGEN
0.3200
+8.47%
0.0250
Oragenics names former GSK exec Kimberly Murphy as CEO
Oragenics (NYSE:OGEN) said Thursday it appointed director Kimberly Murphy as president and CEO effective immediately. Murphy joined OGEN's board in 2020. Most recently, Murphy served as VP of the influenza
Seekingalpha · 1d ago
Oragenics announces peer-reviewed positive data publication for nasal COVID shot candidate
Oragenics (NYSE:OGEN) on Tuesday announced peer-reviewed publication of a co-authored article which concluded that its intranasal COVID-19 vaccine candidate warranted further development. The Tampa, Fla.-based biotech's shares rose 3% to $0.31 in
Seekingalpha · 06/14 13:47
Oragenics Announces Publication Data For Its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate In Scientific Reports
Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronavirus, announces the publication of an article co-authored
Benzinga · 06/14 11:39
BRIEF-Oragenics Announces Publication Of Positive Data For Its Nt-Cov2-1 Intranasal Covid-19 Vaccine Candidate In Scientific Reports
reuters.com · 06/14 11:36
Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports
TAMPA, Fla., June 14, 2022--Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports
Business Wire · 06/14 11:30
Oragenics Chair Sends Letter To Shareholders
Oragenics, Inc. (NYSE:OGEN) (“Oragenics” or the “Company”) today issued the following letter to shareholders from its Executive Chairman, Frederick W. Telling, Ph.D.: To My Fellow
Benzinga · 05/17 11:39
Oragenics Issues Letter to Shareholders
TAMPA, Fla., May 17, 2022--Oragenics Issues Letter to Shareholders
Business Wire · 05/17 11:30
Here's why meme stocks are hinting at another flashy rally for `junk stocks`
We've seen this movie before only to watch dip-buyers get fleeced — but money managers are now warming to the idea of a material bounce in stocks.
Yahoo Finance · 05/13 20:17
Oragenics's Earnings: A Preview
Oragenics (AMEX:OGEN) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Oragenics will report an earnings per share (EPS) of $-0.02.
Benzinga · 04/26 20:04
Oragenics to Participate at the World Vaccine Congress Washington 2022
TAMPA, Fla., April 18, 2022--Oragenics to Participate at the World Vaccine Congress Washington 2022
Business Wire · 04/18 11:30
Executives Buy Around $5.5M Of 3 Penny Stocks
US crude oil futures traded higher on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in ...
Benzinga · 04/04 16:54
4 Penny Stocks Insiders Are Buying
US crude oil futures traded sharply lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...
Benzinga · 03/31 10:16
Oragenics drops after flagging audit concerns
Development stage biotech, Oragenics (OGEN -10.5%) has recorded the biggest intraday loss in a year on Friday after the company said that its financial statements contained an unqualified audit opinion
Seekingalpha · 03/25 18:14
Oragenics Reports Received Audit Opinion Of Going Concern Explanation
Oragenics, Inc. (NYSE:OGEN) (“Oragenics” or the “Company”) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2021, which was filed on
Benzinga · 03/25 11:32
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
TAMPA, Fla., March 25, 2022--Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
Business Wire · 03/25 11:30
Oragenics begins toxicology study in animals to test intranasal COVID-19 vaccine candidate
Oragenics (NYSE:OGEN) starts toxicology study in rabbits to evaluate the safety profile and immunogenicity of its intranasal COVID-19 vaccine candidate, NT-CoV2-1 The company said the study is designed to provide Investigational New
Seekingalpha · 03/22 14:25
Oragenics Initiates Pivotal IND-Enabling Toxicology Study On Its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
Data to establish the safety profile and human dose of vaccine candidate Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") today announced the initiation of a Good Laboratory Practice
Benzinga · 03/22 12:59
Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
TAMPA, Fla., March 22, 2022--Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
Business Wire · 03/22 12:59
Oragenics Initiates Animal Study of COVID-19 Vaccine Candidate
MT Newswires · 03/22 11:23
Oragenics Partners With KBI Biopharma To Produce Material For Its Intranasal COVID-19 Vaccine Candidate
Benzinga · 03/10 16:52
More
Webull provides a variety of real-time OGEN stock news. You can receive the latest news about Oragenics through multiple platforms. This information may help you make smarter investment decisions.
About OGEN
Oragenics, Inc. is a developing-stage company. The Company is focused on developing infectious diseases including coronaviruses and multidrug-resistant organisms. The Company’s pre-clinical product candidates includes OG716 and Terra CoV-2. It, through its subsidiary, is engaged in the research and development of Terra CoV-2 vaccine product candidate. It is also engaged in the development of its lead lantibiotic candidate, OG716, to treat Clostridium difficile.